IRIS
BRANCACCIO, Giuseppina
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.843
NA - Nord America 1.612
AS - Asia 1.234
SA - Sud America 412
AF - Africa 25
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 2
Totale 7.131
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 2.510
US - Stati Uniti d'America 1.582
IE - Irlanda 500
SG - Singapore 468
BR - Brasile 342
GB - Regno Unito 261
CN - Cina 250
HK - Hong Kong 226
VN - Vietnam 128
UA - Ucraina 124
IT - Italia 112
DE - Germania 77
SE - Svezia 57
GR - Grecia 55
FR - Francia 54
KR - Corea 48
AR - Argentina 35
FI - Finlandia 32
TR - Turchia 25
IN - India 18
CZ - Repubblica Ceca 17
MX - Messico 16
BE - Belgio 14
JP - Giappone 14
ID - Indonesia 13
BD - Bangladesh 12
AT - Austria 11
EC - Ecuador 10
ZA - Sudafrica 7
CA - Canada 6
IQ - Iraq 6
PK - Pakistan 6
BO - Bolivia 5
CO - Colombia 5
ET - Etiopia 5
RO - Romania 5
PE - Perù 4
PL - Polonia 4
PY - Paraguay 4
VE - Venezuela 4
AE - Emirati Arabi Uniti 3
DZ - Algeria 3
EU - Europa 3
MA - Marocco 3
NI - Nicaragua 3
AZ - Azerbaigian 2
CL - Cile 2
DO - Repubblica Dominicana 2
HU - Ungheria 2
KE - Kenya 2
LT - Lituania 2
NP - Nepal 2
UZ - Uzbekistan 2
AM - Armenia 1
AO - Angola 1
AU - Australia 1
BB - Barbados 1
BH - Bahrain 1
BY - Bielorussia 1
CH - Svizzera 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
EE - Estonia 1
GE - Georgia 1
IL - Israele 1
JM - Giamaica 1
KG - Kirghizistan 1
KW - Kuwait 1
LY - Libia 1
NL - Olanda 1
NZ - Nuova Zelanda 1
OM - Oman 1
PH - Filippine 1
PS - Palestinian Territory 1
PT - Portogallo 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
TZ - Tanzania 1
UY - Uruguay 1
Totale 7.131
Salva come PNG Salva come JPEG
Città #
Moscow 914
Dublin 500
Chandler 252
Santa Clara 231
Hong Kong 226
Jacksonville 198
Singapore 185
Dallas 80
Princeton 72
Medford 69
Roxbury 65
Houston 54
Beijing 51
New York 51
Seoul 48
Ho Chi Minh City 47
The Dalles 44
Munich 34
Ashburn 33
Wilmington 27
Caserta 26
São Paulo 24
Ann Arbor 22
Des Moines 22
Hanoi 17
Brno 16
Napoli 15
Brussels 14
Nanjing 13
Los Angeles 11
Boardman 10
Bremen 10
Porto Alegre 10
Belo Horizonte 9
Bengaluru 9
Nuremberg 9
Redwood City 9
Woodbridge 9
Haiphong 8
Helsinki 8
San Mateo 8
Brasília 7
Campinas 7
Curitiba 7
Mountain View 7
Changsha 6
Nanchang 6
Rio de Janeiro 6
Rome 6
Shanghai 6
Cambridge 5
Guadalajara 5
Guarulhos 5
Hefei 5
Milan 5
Ninh Bình 5
Tokyo 5
Turku 5
Atlanta 4
Bagheria 4
Belford Roxo 4
Caxias do Sul 4
Clifton 4
Columbus 4
Duque de Caxias 4
Jakarta 4
La Paz 4
Lima 4
Ribeirão Preto 4
Santo André 4
São Bernardo do Campo 4
Zhengzhou 4
Aversa 3
Baghdad 3
Biên Hòa 3
Bogotá 3
Can Tho 3
Contagem 3
Da Nang 3
Fairfield 3
Fortaleza 3
Franca 3
Fuzhou 3
Ha Long 3
Jinan 3
Joinville 3
Lahore 3
Padova 3
Praia Grande 3
Quito 3
Salvador 3
Shenyang 3
Sorocaba 3
Stockholm 3
Tianjin 3
Volta Redonda 3
Ankara 2
Aparecida de Goiânia 2
Araucária 2
Baku 2
Totale 3.694
Salva come PNG Salva come JPEG
Nome #
Detection of in vivo hepatitis B virus surface antigen mutations-A comparison of four routine screening assays 240
Characteristics of liver cirrhosis in Italy: Evidence for a decreasing role of HCV aetiology. 160
3. HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years. 152
Active recruitment strategy in disadvantaged immigrant populations improves the identification of human immunodeficiency but not of hepatitis B or C virus infections 151
AISF position paper on HCV in immunocompromised patients 149
Patologie virali tropicali (Flavivirus, Filovirus, Arenavirus, Bunyavirus, Togavirus: Chikungunya, 146
Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL study 144
Bacterial pneumonia in patients with liver cirrhosis, with or without HIV co-infection: a possible definition of antibiotic prophylaxis associated pneumonia (APAP) 141
Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance 137
Declining prevalence and increasing awareness of HCV infection in Italy: A population-based survey in five metropolitan areas 135
[Prevalence and risk factors for bacteriuria in patients with cirrhosis] 133
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network 129
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 129
Restored Function of HBV-Specific T Cells After Long-term Effective Therapy With Nucleos(t)ide Analogues. 127
A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The ital-c network study 126
Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B ‘e’ antigen-negative chronic hepatitis B genotype D 125
Changing indications for liver transplant: slow decline of hepatitis viruses in Italy 124
Virological patterns of HCV patients with failure to interferon-free regimens. 123
An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C 123
Influenza vaccination in patients with cirrhosis and in liver transplant recipients 119
Different changes in mitochondrial apoptotic pathway in lymphocytes and granulocytes in cirrhotic patients with sepsis. 119
[Cutaneous myiasis from Cordylobia anthropophaga in a traveller returning from Senegal: a case study] 118
Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study 116
Hepatitis delta infection in Italian patients: towards the end of the story? 114
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy. 113
Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows 113
Reactivation of hepatitis B virus in cancer patients treated with chemotherapy for solid tumors. Is the prophylaxis really required? 112
Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long-term tenofovir or entecavir 112
Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta 109
Correction: Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER cohort study (PLoS ONE (2017) 12: 2 (e0172159) DOI: 10.1371/journal.pone.0172159) 109
. Individualized treatment of genotype 1 naïve patients: an Italian multicenter field practice experience 109
Increased liver stiffness in idiopathic pulmonary fibrosis: a pilot study 107
An a prior prediction model of response to peginterferon plus ribavirin dual therapy in naive patients with genotype 1 chronic hepatitis C 107
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 100
Influence of universal HBV vaccination on chronic HBV infection in Italy: Results of a cross-sectional multicenter study 95
Patients with HCV genotype-1 who have failed a direct-acting antiviral regimen: virological characteristics and efficacy of retreatment 93
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 91
Interleukin-28B genetic variants in untreated Italian HCV-infected patients : a multicenter study. 91
LONG TERM SAFETY OF ANTI -TNF ALFA IN PATIENTS WITH INFLAMMATORY ARTHRITIS AND HBV INFECTION: FOCUS ON HEPATITIS B SURFACE ANTIBODY STATUS 87
Recovery of HBV-specific T cell function in patients under long-term effective suppressive therapy by nucleos(t)ide analogues. 87
Identification of Naïve Hcv-1 Patients with Chronic Hepatitis who may Benefit from Dual Therapy with Peg-Interferon and Ribavirin 86
Viral blips during long-term treatment with standard or double dose lamivudine in HBe antigen negative chronic hepatitis B 86
Treatment of Acute Hepatitis C With Ledipasvir and Sofosbuvir in Patients With Hematological Malignancies Allows Early Re-start of Chemotherapy 86
Evolving Clinical Landscape of Chronic Hepatitis B:A Multicenter Italian Study 85
Epidemiological and clinical scenario of chronic liver diseases in Italy: Data from a multicenter nationwide survey 85
Salvage therapy with tenofovir followed by adefovir maintenance in a cirrhotic patient with a lamivudine resistant HBV flare. 83
Gender differences in chronic liver diseases in two cohorts of 2001 and 2014 in Italy 82
Effectiveness and safety of simeprevir-based regimens for hepatitis C in Italy: The STIly observational study 82
Sunscreen ingredients in plasma: a threat for drug-drug interactions and toxicity among patients living with HIV? 80
Effect of direct-acting antivirals on future occurrence of hepatocellular carcinoma in compensated cirrhotic patients 79
Fever of unknown origin (FUO): Which are the factors influencing the final diagnosis? A 2005-2015 systematic review 78
Intermediate and Advanced Hepatocellular Carcinoma Management in four Italian Centers: Patterns of Treatment and Costs 77
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 74
Entecavir monotherapy improves renal function in patients developing renal side effects during long-term tenofovir treatment without compromising virological response: a multicenter real-life study in 103 patients 74
HCV clearance after direct-acting antivirals in patients with cirrhosis by stages of liver impairment: The ITAL-C network study 74
Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis 73
Is spleen circulation impaired in systemic sclerosis and what is the role of liver fibrosis? 72
Patterns of treatment and costs of intermediate and advanced hepatocellular carcinoma management in four Italian centers 72
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 72
Influenza vaccination in patients with cirrosi and in liver transplant recipients. 72
Treatment of chronic hepatitis due to Hepatitis B with Delta virus coinfection 70
The present profile of chronic hepatitis B virus infection highlights future challenges: An analysis of the Multicenter Italian MASTER-B cohort 70
Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir 69
Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals? 68
Individualized treatment of genotype 1 Naïve patients: An Italian multicenter field practice experience 67
Interleukin-28B genetic variants in untreated Italian HCV-infected patients: A multicentre study 67
Ultra-deep sequencing reveals high prevalence and broad structural diversity of hepatitis B surface antigen mutations in a global population 66
Platelets and hepatocellular cancer: Bridging the bench to the clinics 64
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 63
Salvage therapy with follone by adefovir maintenance in a cirrhotic patient with a lamivudine resistant HBV flare. 63
NS5A Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected Patients 59
Hepatitis C Virus Clearance in Older Adults 57
Totale 7.270
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.811
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.811
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021195 0 0 0 0 0 7 59 18 7 29 61 14
2021/2022510 21 9 12 21 174 8 12 24 25 26 36 142
2022/2023928 79 13 12 78 80 76 2 66 482 6 17 17
2023/2024305 29 8 12 8 115 50 0 7 0 6 14 56
2024/2025984 20 23 8 17 168 116 141 56 155 126 89 65
2025/20263.605 113 162 309 274 364 2.383 0 0 0 0 0 0
Totale 7.270